Akebia (AKBA) Therapeutics announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
- Akebia Therapeutics Earnings Call: Vafseo Drives Growth
- 3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
- Akebia reports Q4 EPS (5c), consensus (4c)
- Akebia price target lowered to $4 from $5 at BTIG